Growing evidence suggests that colorectal cancer (CRC) should be subdivided into different prognostic groups defined by molecular biomarker combinations that purportedly reflect the CRC development pathways ([@bib36]; [@bib32]). One such group would be defined by microsatellite instability (MSI) that occurs in ∼15% of sporadic CRCs and leads to significant clinical heterogeneity in both phenotype and survival ([@bib16]).

The most common cause of MSI is sporadic hypermethylation of the promoter area of both *MLH1* alleles, resulting in deficient mismatch repair (MMR; [@bib37]). Microsatellite instability can also occur due to inherited MMR deficiency, such as Lynch syndrome (LS), which involves autosomal-dominant inheritance of a germline mutation in a major MMR gene (*MLH1, MSH2, MSH6,* or *PMS2*) followed by a second mutation later in life.

Numerous clinical and histological features have been proposed to differentiate MSI tumours from microsatellite stable (MSS) tumours. However, it remains uncertain whether these features are clinically useful to the extent required for universal MSI screening, and whether such clinical division into subgroups would be beneficial.

In cases of MSI, the presence of the *BRAF*^*V600E*^ hotspot mutation practically excludes the possibility of LS, and the clinical utility of the combination of these two markers is well established ([@bib10]). *BRAF*^*V600E*^ shows an independent negative prognostic association with survival in MSS CRC ([@bib37]; [@bib29]; [@bib31]), but associations with the combination of MSI and *BRAF* have not been thoroughly investigated. Recent findings indicate that the prognostic potential of MSI overrides the negative prognostic potential of *BRAF*^*V600E*^, thus eliminating the deleterious role of *BRAF*^*V600E*^ within the MSI subgroup ([@bib14]; [@bib19]). International guidelines suggest using both MSI and *BRAF* immunohistochemical (IHC) staining for LS screening algorithms; therefore, these markers are increasingly available for clinical use ([@bib30]; [@bib48]; [@bib47]).

The present study aimed to elucidate the role of MSI and *BRAF*^*V600E*^ in a population-based setting using patient material treated according to 21st century guidelines. The findings provide a basis for the routine clinical use of MMR and *BRAF* status.

Materials and Methods
=====================

Patients
--------

The Central Hospital of Central Finland exclusively serves a defined catchment area of ∼274 000 people around Jyväskylä, Finland. The present study included all consecutive patients (*n*=1088) who underwent major bowel resection for CRC between 2000 and 2010. Tissue microarray (TMA) of a representative tumour sample was available for analysis from 799 patients. Good-quality IHC for MSI were available for 762 patients. Compared with the included subjects, those who dropped out did not substantially differ in age, sex, tumour location, or Union for International Cancer Control (UICC) stage.

Ethical aspects
---------------

The study was approved by the Central Finland Central Hospital\'s ethical committee. Authorisation for use of the patient registry was obtained from the National Supervisory Authority for Welfare and Health (Valvira).

Clinical evaluation
-------------------

Tumours were classified based on their exact location. Tumours situated from the caecum through the transverse colon were deemed proximal colon tumours. Tumours resected from the descending and sigmoid colon from the splenic flexure down to 15 cm proximal from the anal verge were considered distal colon tumours, and those more distally located were classified as rectal tumours. The specimens were macroscopically examined and histologically studied by an experienced histopathologist following UICC guidelines (sixth edition). The histopathologist also performed pTNM staging regarding tumour size and nodal status. Staging was completed (M) by the treating surgeon based on data from imaging and physical examination (usually a body CT scan). Those patients with inadequate specimen for complete pTNM classification (e.g., transanal extirpation of the tumour, *n*=10) were excluded from analyses that required stage. For 574 patients, the operation was elective with a radical result (R0).

Follow-up
---------

For study purposes, a surgeon reviewed all stage assignments along with the pathology and radiology statements, and surgery report. Liver and lung metastases found within 6 months of operation were considered synchronous when determining the final pTNM UICC stage.

Medical records were carefully reviewed. We retrieved information regarding type of surgery (laparoscopic or conventional), parameters reflecting surgical quality, surgical result (i.e., radical/palliative), possible special circumstances (e.g. emergency surgery), and surgical complications. The exact date and location of CRC local or distal recurrence, occurrence of metastases or metachronous CRC, and the possible interventions were also recorded. The dates and official causes of death were retrieved from death certificates, with permission from the Finnish Cause of Death Registry (collected and updated by Statistics Finland, a government authority). In cases of postoperative death (within 30 days), the cause of death and the role of cancer in the event were assessed individually. All medical data regarding preoperative diagnosis, surgery, recurrence, clinical staging, adjuvant treatment, clinical follow-up, and cause of death were re-assessed and recorded to our database by a surgery specialist. The current vital status of each patient was reviewed by confirming deaths from the hospital\'s patient registry or, if uncertain, from the service of the Population Register Centre on the 1 November 2014. Median follow-up was 5.2 years (interquartile range 6.4 years).

Tumour sampling
---------------

The resected specimens were delivered to the pathology department as fresh tissue samples. After formalin fixation and macroscopic evaluation, the tissue samples were embedded in paraffin, and TMA blocks were prepared from the formalin-fixed paraffin-embedded tissue (FFPE) samples. From each FFPE sample, 0.6-mm-diameter tissue cylinders were punched out from the previously marked representative tumour areas and set into a recipient paraffin block using the Manual Tissue Microarrayer MTA-1 (Beecher Instruments Inc., Sun Prairie, WI, USA). From these TMA punches, 2-μm-thick sections were cut. Tissue microarray blocks included one punch from normal mucosa for each patient. One to four representative punches were included from tumour tissue. Four punches were taken from majority of the cases. If the tissue sample was unrepresentative, the data were not included to the statistical analyses.

Immunohistochemistry
--------------------

For all included tumour samples, we performed a universal screening for loss of MMR protein expression. To determine MMR status, IHC analysis was performed for expressions of MLH1, PMS2, MSH2, and MSH6. Following standard procedures, IHC stainings were applied to the 2-μm FFPE TMA sections using the LabVision Autostainer 480 (Thermo Fisher Scientific, Fremont, CA, USA) and BrightVision+polymer detection kit (ImmunoLogic BV, Duiven, The Netherlands). For MLH1, MSH2, MSH6, and PMS2, antigen retrieval was performed by incubation with 1 m[M]{.smallcaps} EDTA/10 m[M]{.smallcaps} Tris/HCl buffer (pH 9) at 99 °C for 15 min. The utilised antibody dilutions were 1 : 100 for *MLH1* (Novocastra, Leica Biosystems, Nussloch, Germany; NCL-L-MLH1), 1 : 150 for MSH2 (Oncogene Research Products, Cambridge, MA, USA; NA27), 1 : 50 for MSH6 (Cell Marque, Rocklin, CA, USA; 287M-16), and 1 : 400 for *PMS2* (BD Pharmingen, Franklin Lakes, NJ, USA; 556415). A 60-min incubation time was used for all antibodies. Normal MLH1, PMS2, MSH2, and MSH6 expressions in tumour samples were detectable as undisputed nuclear staining in neoplastic epithelial cells. Loss of expression was indicated by a lack of expression in tumour cells combined with the staining of internal positive controls (stromal cells or blood vessels). Tissue samples that exhibited positive staining for all four markers were considered MSS. Cases that were undisputedly negative for at least one of the four markers were classified as MSI ([@bib39]).

To determine the *BRAF* status, samples were stained for the *BRAF*^*V600E*^ hotspot mutation using a mutation-specific antibody (clone VE1, Spring Bioscience, Pleasonton, CA, US). Immunohistochemical staining was performed as described above. Antigen retrieval was performed by incubation with 1 m[M]{.smallcaps} EDTA/10 m[M]{.smallcaps} Tris/HCl buffer (pH 8) at 99 °C for 25 min. The antibody was diluted 1 : 100, and a 60-min incubation was used. Positive staining indicated *BRAF*^*V600E*^ while the lack of staining indicated wild-type *BRAF* ([@bib43]). *BRAF*^*V600E*^ mutation-specific antibody is highly sensitive and specific in comparison with PCR-based methods or sequencing ([@bib44]).

The IHC stains for all protein expressions were evaluated by an experienced histopathologist (JPB). In cases with uncertain staining results, a second opinion was obtained from another histopathologist (THIK). Immunohistochemical stainings were always assessed without awareness of the clinical data.

Statistical analysis
--------------------

For analysis, the patients were stratified according to the biological subtypes MSI/MSS and *BRAF*^*V600E*^/*BRAF* wild type, both separately and in combinations.

For categorical variables, *χ*^2^-tests or contingency tables were used to investigate the differences between MSI, MSS, *BRAF*^*V600E*^, and *BRAF* wild-type groups, and the total population. Multiple-group differences were tested using one-way analysis of variances with Bonferroni *post hoc* correction. A *P*-value \<0.05 was considered statistically significant. Statistical analyses were performed using SPSS Statistics for Mac (release 19.0.0; SPSS Inc., Chicago, IL, USA).

Kaplan--Meier analysis was used to create survival curves, and a log-rank test was used to test the between-subgroup differences in survival curves. Cox regression with proportional hazard analysis was used to evaluate the survival hazard ratio (HR) between groups. Regression models included adjustments for age, sex, tumour location, American Society of Anaesthesiologists (ASA) class, and type of surgery. Separate analyses were conducted to evaluate overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS; relapse-free survival). Only variables with *P*≤0.20 in univariate analysis were entered in the multivariate analysis. For analysis of CRC-specific survival, patients who died from causes other than CRC were censored to the date of death. For analysis of DFS, the date of CRC recurrence after radical surgery was used as an end point. Subjects who were operated with a known non-radical result or who died within 30 days postoperatively for causes other than CRC were excluded from analyses of DSS or DFS.

Results
=======

The final analysis included a total of 762 patients with IHC results for four tumour MSI markers. Of these patients, 111 (14.6%) showed a loss of MMR protein expression that was considered the result of MSI, and 94 (12.3%) had tumours with *BRAF*^*V600E*^. *BRAF*^*V600E*^ was found in 60 cases with MSI (54%) and 34 cases of MSS (5.2%). Only six out of 191 rectum cancer patients had an MSI tumour, of which three also included *BRAF*^*V600E*^.

Age and sex
-----------

[Tables 1A](#tbl1A){ref-type="table"} and [1B](#tbl1B){ref-type="table"}, present the demographical information of the study population and the subgroups, together with tumour location, staging, molecular markers, lymph node harvest, and follow-up data. Microsatellite instability prevalence increased with age in the study population. Microsatellite instability was strongly associated with female gender, proximal tumour location, and poorly differentiated histology. Compared with men, women showed higher incidences of both MSI and *BRAF*^*V600E*^. Microsatellite instability incidence increased with age among women but not in men ([Table 2](#tbl2){ref-type="table"}). We identified no sex-related differences in the distribution of tumour stages or differentiation (grade). Patients with tumours with *BRAF*^*V600E*^ were older than those with *BRAF* wild type. Accordingly, patients of the MSI *BRAF*^*V600E*^ subtype were significantly older than other groups.

Tumour invasion and metastases
------------------------------

In general, MSI tumours were less likely to have metastasised to local lymph nodes (LN) compared with MSS tumours (30.5 *vs* 42.2%). The LN harvest was 15 LN/specimen in MSI tumours, 11 LN/specimen in MSS tumours, 15 LN/specimen in *BRAF*^*V600E*^ tumours, and 11 LN/specimen in *BRAF* wild-type tumours. Among MSS/*BRAF*^*V600E*^ tumours, 64.7% were nodal positive (N+ [Table 1A](#tbl1A){ref-type="table"}).

Compared with MSI tumours, MSS tumours were more than three times more likely to have sent distant metastases (M+). M+ cases comprised 47.1% of the MSS/*BRAF*^*V600E*^ subtype and only 3.3% of the MSI/*BRAF*^*V600E*^ subtype. Accordingly, stage IV was most common in the MSS/*BRAF*^*V600E*^ group and least common among MSI cases irrespective of *BRAF* status ([Table 1A](#tbl1A){ref-type="table"}). Right-sided tumours were associated with MSI and *BRAF*^*V600E*^, being most common in the MSI/ *BRAF*^*V600E*^ subgroup ([Table 1B](#tbl1B){ref-type="table"}).

Impact of MSI and *BRAF* status to prognosis
--------------------------------------------

In the total study population, including the patients who underwent operations for emergency conditions or palliation, the overall 5-year survival was 60.8% and DSS was 72.3% ([Table 3](#tbl3){ref-type="table"}). Among all electively and radically operated patients (R0; *n*=574) the 5-year DSS was 85.0% and DFS was 78.6%. Compared with the other subtype groups, *BRAF*^*V600E*^ MSS tumours were more likely to develop recurrence during follow-up after elective operation with radical outcome, but the subgroups were too small to reliably compare locoregional and distal recurrences ([Table 1B](#tbl1B){ref-type="table"}).

Compared with MSS cancer, MSI was a prognostic factor for DFS and DSS (5-year DFS: 75.3% *vs* 85.8%, 10-year DFS: 72.9% *vs* 85.8%, *P*=0.027; 5-year DSS: 70.5% *vs* 83.2%, 10-year DSS: 65.0% *vs* 83.2%, *P*=0.004; [Figure 1A](#fig1){ref-type="fig"}), but not for OS in univariate analysis. *BRAF*^*V600E*^ alone was an adverse prognostic factor for OS (5-year OS: 52.2% *vs* 62.3%, *P*=0.014) but not for CRC-specific survival. For DSS, univariate analysis showed that the HR for MSI *vs* MSS was 0.49 (CI: 0.30--0.80, *P*=0.005). Univariate analysis of *BRAF*^*V600E*^ *vs BRAF* wild type revealed HR values of 1.14 (CI: 0.98--1.33, *P*=0.088) for DSS and 1.43 (CI: 1.07--1.90, *P*=0.015) for OS.

Prognostic factors in multivariate analysis
-------------------------------------------

UICC stage, operation type, and combinations of MSI/MSS and *BRAF*^*V600E*^/*BRAF* wild type were significant in univariate analysis, and therefore entered in all multivariate analyses. In addition, age, sex, and ASA class were included in the model of OS. Both MSI and *BRAF*^*V600E*^ alone lost their independent prognostic significance when UICC stage was added to the model. *BRAF*^*V600E*^ seemed to show a negative effect on DSS in rectal cancer in a multivariate model, but the numbers were small (for DSS, HR: 10.60, CI: 3.04--36.92, *P*\<0.001; for OS, HR: 4.51, CI: 1.92--10.60, *P*\<0.001; *n*=8; [Figure 1B](#fig1){ref-type="fig"}).

[Table 4](#tbl4){ref-type="table"} presents multivariate analyses for combinations of MSI/MSS and *BRAF*^*V600E*^/*BRAF* wild type. The MSS/*BRAF*^*V600E*^ subtype was an independent factor associated with poor DSS and OS (for DSS, HR: 1.88, CI: 1.06--3.31, *P*=0.030; [Figure 1C](#fig1){ref-type="fig"}; for OS, HR: 1.87, CI: 1.17--3.00, *P*=0.009). Univariate analysis showed a protective effect of the MSI/*BRAF*^*V600E*^ subtype (for DSS, HR: 0.47, CI: 0.23--0.96, *P*=0.039) compared with MSS/*BRAF* wild type, but the difference did not reach significance in the multivariate model. However, the MSI/*BRAF*^*V600E*^ subtype was an independent prognostic factor for better DFS in the multivariate model (HR: 0.42, CI: 0.18--0.96, *P*=0.039). Among patients with stage I--II tumours, MSS/*BRAF*^*V600E*^ subtype was an independent factor for poor DSS compared with MSS/*BRAF* wild type (HR: 5.32, CI: 1.74--16.31, *P*=0.003; [Figure 1D](#fig1){ref-type="fig"}).

Discussion
==========

MSI CRCs have a favourable prognosis despite their characteristically poor histological differentiation ([@bib7]; [@bib4]; [@bib37]). They also have a reduced likelihood of both local and distal metastasis, which is suggested by the lower incidence of stages III--IV ([@bib21]; [@bib15]). Microsatellite instability contributes to improved survival by predicting a lower pathologic stage at diagnosis, and predicts more favourable outcome even within the same stage ([@bib12]; [@bib33]; [@bib4]).

This study presents the results of analysing tumour samples from a population-based cohort of CRC patients who were residing within a defined catchment area and treated by modern guidelines in the 2000s. Our findings demonstrate the prognostic relevance of MSI/*BRAF*^*V600E*^ subtyping in a real-life clinical setting. Our data confirmed some previous inconsistent findings, including the favourable CRC-specific prognosis of MSI/*BRAF*^*V600E*^ tumours compared with MSS/*BRAF* wild-type tumours, which was suspected by Lochhead *et al* ([@bib19]; [@bib45]). We also confirmed the previously described negative prognostic effect of *BRAF*^*V600E*^ among MSS tumours ([@bib37]; [@bib28]; [@bib35]; [@bib31]; [@bib45]; [@bib32]), but we did not find any prognostic significance of *BRAF*^*V600E*^ within the MSI group.

Strikingly, among patients with stage I--II CRC, we found a patient subgroup with a significantly worse survival than others, which may impact current adjuvant treatment guidelines. The main unanswered clinical question related to MSI and *BRAF* status relates to the need for and usefulness of postoperative adjuvant therapy in stage I--III CRC. Our present findings indicate that patients with the MSS/*BRAF*^*V600E*^ subtype are in danger of increased CRC mortality even in stage I--II and require a more aggressive adjuvant treatment approach ([Figure 1D](#fig1){ref-type="fig"}). Combinations with fluorouracil-based (5FU) chemotherapy reportedly do not improve DFS of MSI patients, but improve the course of MSS CRC ([@bib38]). Also, patients with MSI tumours generally do well without chemotherapy ([@bib15]). In the present study, only stage III and IV patients were referred to an oncologist for adjuvant chemotherapy---primarily FOLFOX (folic acid+5FU+oxaliplatin) or FOLFIRI (folic acid+5FU+irinotecan). Among the stage III MSI CRC patients, 74% received adjuvant chemotherapy, without showing any survival benefit compared with those who did not (data not shown). It might be beneficial to further target adjuvant chemotherapy to the stage III MSI CRC patients with the worst prognosis. The rationale behind also administering adjuvant chemotherapy to the stage II MSS CRC patients with the worst prognosis should be studied further.

In our study, the eight subjects with rectal cancer and a *BRAF*^*V600E*^ showed extremely poor survival, with an HR of 10.6 for CRC death ([Figure 1C](#fig1){ref-type="fig"}). This differs from the findings in a series of 11 patients presented by [@bib31] and from the results presented by [@bib37], in which the rectum cancer was not reported to stand out with substantially worse prognosis. Most studies include only small numbers of rectal cancer cases, if any, compared with colon cancer cases. Furthermore, *BRAF*^*V600E*^ seems to be rare in rectal cancer. The present finding of a potentially worse prognosis in MSS/*BRAF*^*V600E*^ rectal cancer compared with MSS/*BRAF*^*V600E*^ colon cancer has not been previously reported, and must be verified in a larger setting.

Many of our patients were followed up to over 10 years. No disease-specific CRC deaths occurred in the MSI group after 2.7 years, but events continued to occur even up to 10 years in the MSS group ([Figure 1A](#fig1){ref-type="fig"}). In addition, only one recurrence was noted in the MSI group after 2 years of DFS (at 4.8 years), whereas several recurrences were observed in the MSS group even after 5 years. Most previous studies have only reported the 5-year DSS and DFS. These observations may suggest that different follow-up schedules should apply according to MSI status.

We found a significant difference in the LN yield related to MSI, which is a relatively new finding. Earlier reports have described the possible macroscopic growth of LNs ([@bib40]) and consequent greater LN harvest ([@bib3]; [@bib5]). Despite the higher number of LNs found, there were significantly fewer LN metastases in MSI CRCs ([Table 1A](#tbl1A){ref-type="table"}). As patients with MSI tumours have better outcome than patients with MSS tumours ([@bib12]; [@bib33]; [@bib1]; [@bib24]), the peritumoural immune response may play an imperative role in the defence ([@bib11]). The improved survival may be owing to a high number of cytotoxic T lymphocytes and other favourable differences in the tumour microenvironment ([@bib13]; [@bib6]; [@bib34]). Our hypothesis is that the more prominent immune response in MSI leads to LN enlargement to a more easily detectable and macroscopically visible size. However, there may be other explanations. The greater LN harvest could also have resulted from the balance between right/left and colon/rectum in our material, as there was a considerable shift towards right-sided colon tumours in MSI. In addition, rectal tumours tend to have fewer investigated LNs.

We observed a large overlap between MSI and *BRAF*^*V600E*^ tumours, with 60 of the 94 *BRAF*^*V600E*^ tumours (64%) also classified as MSI. Interestingly, the poor survival effect caused by *BRAF*^*V600E*^ was practically overpowered by the favourable effect of MSI in the MSI/*BRAF*^*V600E*^ subgroup. Hence, MSI status should always be included in studies that address *BRAF* mutation status ([@bib14]).

Some clinical features of MSI have been well described over the last two decades. The nearly 15% prevalence of MSI in our study is comparable to previously reported values ([@bib16]) and to a similar series in northern Europe ([@bib24]), but not to the prevalence in EPICOLON (7.4% [@bib26]). Microsatellite instability tumours are more commonly situated in the proximal colon, whereas MSS tumours tend to be equally distributed between proximal and distal sites ([@bib17]; [@bib12]; [@bib49]; [@bib8]). As found in our present material, histology substantially differs between MSI tumours and those with proficient MMR. Microsatellite instability tumours often have a mucinous phenotype, and show intraepithelial and peritumoural lymphocytic infiltration and prominent inflammatory reaction compared with chromosomally instable tumours ([@bib20]; [@bib42]; [@bib12]; [@bib33]).

Our findings confirmed that female gender was associated with increasing MSI prevalence with age, while MSI frequency remained stable in men despite age. Most recent studies have also described an association of female gender with MSI ([@bib22]; [@bib21]; [@bib32]). The increase of incidence has been proposed to be based on the effects of oestrogen withdrawal with increasing age, as oestrogen protects against tumour instability by decreasing the promoter methylation ([@bib25]; [@bib18]). The female gender predominance may also be linked to a serrated pathway. Serrated pathway proximal adenocarcinomas are concentrated in females ([@bib36]), even though serrated adenomas are more common in males ([@bib46]). In our present study material, female patients had more proximal colon tumours than men, and MSI was significantly more common in proximal tumours. It remains unknown why women have a higher rate of conversing serrated adenomas into adenocarcinomas, but sporadic MSI carcinomas are more frequent in women, occur at an older age, and often have a serrated morphology ([@bib50]). Patients who exhibit sporadic colon cancer within 5 years after colonoscopy are more likely to have an MSI tumour than those who are diagnosed \>5 years after their last colonoscopy ([@bib27]). They are also more likely to be female and to have tumours at a proximal location in the colon ([@bib9]). About 18% of proximal adenocarcinomas in women are serrated and they are linked to MSI predominance, which may provide a clinically relevant reason for close follow-up of serrated right adenomas in females ([@bib41]; [@bib23]).

The current study has several limitations. All molecular analyses were conducted blinded to the clinical data, but the patient history and follow-up were obtained from the medical records and are thus retrospective by nature. The subgroup analyses are statistically solid, but the case numbers are small---especially regarding rectal cancer---and should be interpreted with caution. In addition, the clinical relevance of MSI as a prognostic factor has been criticised because most previous population-based studies have analysed samples from the 1980s and 1990s, before many modern developments in tumour staging and adjuvant chemotherapy ([@bib21]). Furthermore, one large well-designed study did not show that MSI influences prognosis ([@bib2]). It is problematic to analyse the OS advantage of patients with MSI tumours, as many patients develop sporadic MSI CRC at an old age and other causes of death complicate the analysis ([@bib21]). Strengths of our study are that our material was from a defined catchment area and was collected entirely within the era during which staging was based on current guidelines; therefore, our data can be interpreted to corroborate the favourable effect of MSI. We also provided DFS and DSS in addition to OS, as well as an adequate follow-up length compared with studies with OS only ([@bib45]). Our cohort of patients is well characterised and the follow-up time is long, but it is evident that further studies using other independent cohorts would be valuable to validate our results and conclusions. Therefore, we are seeking for collaboration with other groups of investigators with large and representative patient materials.

Overall, our data support the easy and inexpensive universal IHC screening of all CRC tumours for MSI and *BRAF* status. Tumour MSI can predict a lower risk of cancer-related death--regardless of standard prognostic factors, including tumour local invasion, but not independently of TNM classification. TNM classification only accounts for the current disease stage without predicting how aggressively the tumour may behave or how effective the immune response will be in defence. Some subgroups of patients may perform worse despite a less advanced TNM stage, thus warranting more specific subtyping of CRC. Microsatellite instability and *BRAF* are likely to complement the TNM classification and provide additional value to clinical prognostic evaluation.
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![(**A**) Colorectal cancer (CRC) disease-specific survival (DSS) of patients with microsatellite instable (MSI; *n*=111, green line) and with microsatellite stable (MSS) tumours (*n*=651, blue line). Five-year survival: MSI, 83.2%, MSS, 70.5%. Ten-year survival: MSI, 83.2% MSS, 65.0%. *P*=0.004 for log-rank test (Mantel--Cox). (**B**) Rectal cancer DSS of patients with *BRAF*^*V600E*^ (*n*=8, green line) and wild-type *BRAF* tumours (*BRAF* wild type, *n*=185, blue line). Five-year survival: *BRAF* wild type, 73.3% *BRAF*^*V600E*^, 28.6%. Ten-year survival: *BRAF* wild type, 46.3% *BRAF*^*V600E*^, 0%. *P*\<0.001 for log-rank test (Mantel--Cox). (**C**) Colorectal cancer DSS of subtypes according to the following combinations of MSI and *BRAF* status: MSI/*BRAF* wild type (*n*=44, yellow line), MSI/*BRAF*^*V600E*^ (*n*=60, purple line), MSS/*BRAF* wild type (*n*=600, blue line), and MSS/*BRAF*^*V600E*^ (*n*=34, green line). Five-year survival: MSI/*BRAF* wild type, 80.7% MSI/ *BRAF*^*V600E*^, 84.6% MSS/*BRAF* wild type, 72.8% MSS/*BRAF*^*V600E*^, 40.5%. *P*\<0.001 for log-rank test (Mantel--Cox). (**D**) Colorectal cancer DSS of patients with stage I--II disease according to the following combinations of MSI and *BRAF* status: MSI/*BRAF* wild type (*n*=33, yellow line), MSI/*BRAF*^*V600E*^ (*n*=35, purple line), MSS/*BRAF* wild type (*n*=329, blue line), and MSS/*BRAF*^*V600E*^ (*n*=9, green line). Five-year survival: MSI/*BRAF* wild type 93.4% MSI/*BRAF*^*V600E*^ 92.9% MSS/*BRAF* wild type 89.0% MSS/*BRAF*^*V600E*^ 70.0%. *P*=0.031 for log-rank test (Mantel--Cox); MSS/*BRAF*^*V600E*^ *vs* MSS/*BRAF* wild type.](bjc2015160f1){#fig1}

###### Demographical information stratified by molecular genetic subtypes

  **Factor**             **All**   **%**    **MSI**   **%**    **MSS**   **%**    ***P***   ***BRAF***^***V600E***^   **%**    ***BRAF*** **wild type**   **%**    ***P***   **MSI/*****BRAF***^***V600E***^   **%**    **MSI*****/BRAF*** **wild type**   **%**    **MSS/*****BRAF***^***V600E***^   **%**    **MSS/*****BRAF wild type***   **%**    ***P***
  --------------------- --------- -------- --------- -------- --------- -------- --------- ------------------------- -------- -------------------------- -------- --------- --------------------------------- -------- ---------------------------------- -------- --------------------------------- -------- ------------------------------ -------- ---------
  *N*                      762      100       111      14.6      651      85.4                        94               12.3              644               87.7                            60                   7.9                    44                   5.8                   34                   4.5                 600                 81.3        
  **Age (years)**                                                                                                                                                                                                                                                                                                                                     
  Mean (s.d.)             70.3     (11.5)    72.1     (12.8)    69.9     (11.2)    0.064             74.1             (10.8)             69.7             (11.5)   \<0.001                76.1                 (9.0)                  66.2                 (15.5)                70.4                 (12.6)                70                (11.1)   \<0.001
  \<50                     37       4.9        9       8.1       28       4.3      0.007               1               1.1                33               5.1      0.117                   0                    0                     9                    20.5                   1                   2.9                  24                 4.0      0.001
  50--60                   103      13.5       7       6.3       96       14.7                        11               11.7               90               14.0                             3                   5.0                    4                    9.1                    8                   23.5                 86                 14.3        
  60--70                   186      24.4      23       20.7      163      25.0                        16               17.0              164               25.5                            11                   18.3                   9                    20.5                   5                   14.7                155                 25.8        
  70--80                   274      36.0      38       34.2      236      36.3                        35               37.2              230               35.7                            25                   41.7                   11                   25.0                  10                   29.4                219                 36.5        
  \>80                     162      21.3      34       30.6      128      19.7                        31               33.0              127               19.7                            21                   35.0                   11                   25.0                  10                   29.4                116                 19.3        
  **Sex**                                                                                                                                                                                                                                                                                                                                             
  Male                     370      48.6      35       31.5      335      51.5    \<0.001             32               34.0              330               51.2     0.005                  16                   26.7                   16                   36.4                  16                   47.1                314                 47.7    \<0.001
  Female                   392      51.4      76       68.5      316      48.5                        62               66.0              314               48.8                            44                   73.3                   28                   63.6                  18                   52.9                286                 52.3        
  ***T***                                                                                                                                                                                                                                                                                                                                             
  1                        56       7.3        5       4.5       51       7.8      0.103               2               2.1                51               7.9      0.008                   2                   3.3                    1                    2.3                    0                    0                   50                 8.3      0.002
  2                        130      17.1      13       11.7      117      18.0                         7               7.4               121               18.8                             6                   10.0                   7                    15.9                   1                   2.9                 114                 19.0        
  3                        453      59.4      69       62.2      384      59.0                        67               71.3              373               57.9                            44                   73.3                   23                   52.3                  23                   67.6                350                 58.3        
  4                        123      16.1      24       21.6      99       15.2                        18               19.1               99               15.4                             8                   13.3                   13                   29.5                  10                   29.4                 86                 14.3        
  ***N***                                                                                                                                                                                                                                                                                                                                             
  0                        447      59.7      76       68.5      371      58.1     0.096              50               53.2              382               60.3     0.106                  38                   63.3                   33                   75.0                  12                   35.3                349                 59.2     0.019
  1                        197      26.2      21       18.9      176      27.5                        25               26.6              166               26.2                            13                   21.7                   8                    18.2                  12                   35.3                158                 26.8        
  2                        108      14.4      14       12.6      94       14.7                        19               20.2               86               13.6                             9                   15.0                   3                    6.8                   10                   29.4                 83                 13.8        
  \+                       305      40.6      35       30.5      270      42.2     0.023              44               46.8              252               39.8     0.032                  22                   36.7                   11                   25.0                  22                   34.7                242                 40.6     0.005
  **LN yield**                                                                                                                                                                                                                                                                                                                                        
  Mean (s.d.)             11.6     (12.9)    15.5     (27.2)     11      (8.2)    \<0.001            15.1             (28.8)             11.2             (8.4)     0.006                 18.2                 (35.6)                 11.5                 (9.5)                  9.7                 (5.9)                10.4               (11.2)   \<0.001
  ***M***                                                                                                                                                                                                                                                                                                                                             
  0                        652      86.7      107      96.4      545      85.0    \<0.001             76               80.9              554               87.4     0.257                  58                   96.7                   42                   95.5                  18                   52.9                512                 86.8    \<0.001
  1                        100      13.3       4       3.6       96       15.0                        18               19.1               80               12.6                             2                   3.3                    2                    4.5                   16                   47.1                 78                 13.2        
  **UICC stage**                                                                                                                                                                                                                                                                                                                                      
  I                        147      19.5      17       15.3      130      20.3    \<0.001              8               8.5               137               21.6     0.011                   7                   11.7                   8                    18.2                   1                   2.9                 129                 21.9    \<0.001
  II                       272      36.2      56       50.5      216      33.7                        36               38.3              225               35.5                            28                   46.7                   25                   56.8                   8                   23.5                200                 33.9        
  III                      233       31       34       30.6      199      31.0                        32               34.0              192               30.3                            23                   38.3                   9                    20.2                   9                   26.5                183                 31.0        
  IV                       100      13.3       4       3.6       96       15.0                        18               19.1               80               12.6                             2                   3.3                    2                    4.5                   16                   47.1                 78                 13.2        
  **Tumour location**                                                                                                                                                                                                                                                                                                                                 
  Proximal colon           323      42.4      86       77.5      237      36.5    \<0.001             75               79.8              237               36.8    \<0.001                 53                   88.3                   26                   59.1                  22                   64.7                211                 35.2    \<0.001
  Distal colon             241      31.7      19       17.1      222      34.2                        11               11.7              222               34.5                             4                   6.7                    15                   34.1                   7                   20.6                207                 34.5        
  Rectum                   197      25.9       6       5.4       191      29.4                         8               8.5               184               28.6                             3                   5.0                    3                    6.8                    5                   14.7                181                 30.2        

Abbreviations: LN=lymph node; MSI=microsatellite instability; MSS=microsatellite stable; UICC=Union for International Cancer Control.

BRAF status was missing for 24 subjects.

UICC stage, *N* and *M* missing for 10 subjects.

Tumour recurrence applicable for those with elective surgery and radical outcome (R0) (*n*=574). Statistical difference for locoregional/distal recurrence not applicable due to small numbers for MSI/BRAF subtypes.

For MSS/BRAFV600e *vs* MSI/BRAFV600E, *P*=0.028, log-rank test (Mantel--Cox). Exact location was missing for one subject (colon).

###### Demographical information and follow-up data stratified by molecular genetic subtypes

  **Factor**                                           **All**   **%**   **MSI**   **%**   **MSS**   **%**   ***P***   ***BRAF***^***V600E***^   **%**   ***BRAFwild type***   **%**   ***P***    **MSI/*****BRAF***^***V600E***^   **%**   **MSI*****/BRAFwild type***   **%**   **MSS/*****BRAF***^***V600E***^   **%**   **MSS/*****BRAF wild type***   **%**                ***P***
  --------------------------------------------------- --------- ------- --------- ------- --------- ------- --------- ------------------------- ------- --------------------- ------- ---------- --------------------------------- ------- ----------------------------- ------- --------------------------------- ------- ------------------------------ ------- -----------------------------------
  *N*                                                    762      100      111     14.6      651     85.4                        94              12.3            644           87.7                             60                   7.9                44                 5.8                  34                   4.5                600                81.3                     
  **Tumour location**                                                                                                                                                                                                                                                                                                                                             
  Proximal colon                                         323     42.4      86      77.5      237     36.5    \<0.001             75              79.8            237           36.8    \< 0.001                 53                  88.3                26                59.1                  22                  64.7                211                35.2                 \<0.001
  Distal colon                                           241     31.7      19      17.1      222     34.2                        11              11.7            222           34.5                              4                   6.7                15                34.1                   7                  20.6                207                34.5                     
  Rectum                                                 197     25.9       6       5.4      191     29.4                         8               8.5            184           28.6                              3                   5.0                 3                 6.8                   5                  14.7                181                30.2                     
  **MSI status**                                                                                                                                                                                                                                                                                                                                                  
  MSI                                                    111     14.6       0        0       111      100                        60              63.8            44             6.8    \< 0.001                 60                   100                44                 100                   0                    0                  0                   0                  \<0.001
  MSS                                                    651     85.4      651      100       0        0                         34              36.2            600           93.2                              0                    0                  0                  0                   34                   100                600                 100                     
  ***BRAF*** **status**                                                                                                                                                                                                                                                                                                                                           
  *BRAF*^*V600E*^                                        94      12.3      60      54.1      34       5.2    \<0.001             94               100             0              0                              60                   100                 0                  0                   34                   100                 0                   0                      
  *BRAF-wt*                                              644     84.5      44      39.6      600     92.2                         0                0             644            100                              0                    0                 44                 100                   0                    0                 600                 100                     
  Missing                                                24       3.1       7       6.3      17       2.6                                                                                                                                                                                                                                                                           
  **Adjuvant chemo**                                                                                                                                                                                                                                                                                                                                              
  Chemo                                                  272     64.3      37      33.3      235     36.1     0.327              36              38.3            225           34.9     0.388                   21                  35.0                14                31.8                  15                  44.1                211                35.2                  0.707
  No chemo                                               490     35.7      74      66.7      416     63.9                        58              61.7            419           65.1                             39                  65.0                30                68.2                  19                  55.9                389                64.8                     
  **Cancer recurrence**[a](#t1B-fn5){ref-type="fn"}                                                                                                                                                                                                                                                                                                               
  −                                                      449     78.2      80      87.8      369     76.2     0.035              52              82.5            386           78.1     0.452                   43                  89.6                31                86.1                   9                  60.0                355                77.5                  0.005
  \+                                                     125     21.8      10      11.4      115     23.8                        11              17.5            108           21.9                              5                  10.4                 5                13.9                   6                  40.0                103                22.5                     
  Locoregional                                           36      28.8       5      50.0      31      27.0      NA                 2              18.2            32            29.2     0.079                    1                  20.0                 4                80.0                   1                  16.7                 28                27.2                   NA
  Distant                                                74      59.2       1      10.0      73      63.5                         5              45.5            66            61.1                              0                    0                  1                20.0                   5                  83.3                 65                63.1                     
  Locoregional and distant                               15      12.0       4      40.0      11       9.6                         4              36.4            10             9.4                              4                  80.0                 0                  0                    0                    0                  10                 9.7                     
  **5-Year survival, %**                                                                                                                                                                                                                                                                                                                                          
  OS                                                    60.8              67.1              59.7              0.293             51.6                            62.3                    0.009                  64.1                                    70.4                                    29.4                                     61.8                                    \<0.001
  DSS                                                   72.3              83.2              70.5              0.004             69.1                            73.3                    0.305                  84.6                                    80.7                                    40.5                                     72.8                                    \<0.001
  DFS                                                   76.9              85.8              75.3              0.027             81.9                            76.8                    0.334                  88.2                                    82.8                                    63.1                                     76.9                       0.139[b](#t1B-fn6){ref-type="fn"}

Abbreviations: Chemo=chemotherapy; DFS=disease-free survival; DSS=disease-specific survival; MSI=microsatellite instability; MSS=microsatellite stable; NA=not applicable; OS=overall survival; UICC=Union for International Cancer Control.

BRAF status was missing for 24 subjects.

UICC stage, *N* and *M* missing for 10 subjects.

Exact location was missing for one subject (colon).

Tumour recurrence applicable for those with elective surgery and radical outcome (R0) (*n*=574). Statistical difference for locoregional/distal recurrence is not applicable due to small numbers for MSI/BRAF subtypes.

For MSS/BRAFV600e *vs* MSI/BRAFV600E *P*=0.028, log-rank test (Mantel-Cox).

###### MSI prevalence and case demographical information by gender

                         **Male**                         **Female**                   
  --------------------- ---------- ----------- --------- ------------ ----------- ---------
  **Total**                370      35 (9.5)                 392       79 (19.8)       
  **Age (years)**                                                                 
  \<50                      13      3 (23.1)     0.544        24       6 (25.0)     0.011
  50--60                    49       4 (8.2)                  54        3 (5.6)        
  60--70                    93       9 (9.7)                  93       14 (15.0)       
  70--80                   153      13 (8.5)                 121       25 (20.7)       
  \>80                      62       6 (9.7)                 100       28 (28.0)       
  **Tumour location**                                                             
  Proximal colon           138      26 (18.8)   \<0.001      185       60 (32.4)   \<0.001
  Distal colon             113       6 (5.3)                 128       13 (10.2)       
  Rectum                   118       3 (2.5)                  79        3 (3.8)        
  **Stage**                                                                       
  I                         78       6 (7.7)     0.222        69       11 (15.9)    0.008
  II                       124      16 (12.9)                148       40 (27.0)       
  III                      108      11 (10.2)                125       23 (18.4)       
  IV                        57       2 (3.5)                  43        2 (4.7)        
  **Grade**                                                                       
  G1                       114       8 (7.0)     0.006       133       20 (15.2)   \<0.001
  G2                       209      16 (7.7)                 196       27 (13.8)       
  G3 (+mucinous)            47      11 (23.4)                 61       28 (45.9)       
  G4                        0           0                     2        1 (50.0)        

Abbreviations: MSI=microsatellite instability; UICC=Union for International Cancer Control.

*P*-value for *χ*^2^-tests, MSI subgroup *vs* total within gender.

UICC stage missing for 10 subjects (3 males and 7 females). Exact location missing for one subject (male).

###### Colorectal cancer disease-specific 5-year survival in MSI and MSS (%)

                  **All**   **MSI**   **MSS**   **Colon**   **Rectum**   **MSI colon**   **MSS colon**
  -------------- --------- --------- --------- ----------- ------------ --------------- ---------------
  *N*               752       111       651        561         191            105             456
  Stage I          94.6      100.0     94.0       96.1         92.3          100.0           95.4
  Stage II         86.0      92.0      84.4       86.8         82.6          91.7            85.2
  Stage III        67.9      71.6      67.4       68.3         66.7          72.8            67.5
  Stage IV         14.0      25.0      14.6       12.3         18.2           0.0            13.1
  All patients     72.3      83.2      70.5       72.4         72.1          83.3            69.9

Abbreviations: MSI=microsatellite instability; MSS=microsatellite stable.

Table includes all elective, palliative and emergency surgery.

Results are from Kaplan--Meier analysis.

For 10 patients, the TNM stage was incomplete due to transanal or endoscopic removal of the tumor.

###### Overall, colorectal cancer disease-specific and disease-free survival by tumor subtype, HRs followed by CIs for Cox regression

                                            **Overall survival**           **Disease-specific survival**           **Disease-free survival**      
  ---------------------------------- ----- ---------------------- ------- ------------------------------- ------- --------------------------- -------
  **MSS/*****BRAF-*****wild-type**    600            1                                   1                                     1                  
  **MSI/*****BRAF***^***V600E***^     60     0.83 (0.54--1.27)     0.386         0.58 (0.28--1.18)         0.131       0.42 (0.18--0.96)       0.039
  **MSI/*****BRAF-*****wild-type**    44     1.16 (0.68--1.97)     0.579         1.04 (0.48--2.25)         0.93        0.86 (0.40--1.85)       0.694
  **MSS/*****BRAF***^***V600E***^     34     1.87 (1.17--3.00)     0.009         1.88 (1.06--3.31)         0.03        1.36 (0.59--3.15)       0.468

Abbreviations: ASA=American Society of Anaesthesiologists; CI=confidence interval; HR=hazard ratio; MSI=microsatellite instability; MSS=microsatellite stable; UICC=Union for International Cancer Control.

Models were adjusted for age, sex, UICC stage, ASA class and operation type.

MSS/BRAF wild type is reference category.

[^1]: These authors contributed equally to this work.
